SLC5A2 and kidney failure: SGLT-2 inhibitors demonstrate significant benefits in several areas: slowing the decline in eGFR, delaying kidney failure, reducing the incidence of ESRD, lowering cardiovascular mortality and heart failure hospitalizations, and improving cardiovascular health (84).